Alzheimer’s Drug Trials Halted by Johnson & Johnson and Pfizer
Tuesday, August 7, 2012 - 02:00
in Health & Medicine
The companies developing the treatment, called bapineuzumab, said it did not improve cognition or daily functioning compared with a placebo.